Results 161 to 170 of about 199,597 (317)

Mammalian evolution and human mutation burden in Rab GTPases. [PDF]

Biochem Biophys Rep
Sidor U, Hughes GM, Simpson JC.
europepmc   +1 more source

In vitro and in silico modelling of ROS1‐positive non‐small cell lung cancer reveals fusion‐dependent tyrosine kinase inhibitor responses

Molecular Oncology, EarlyView.
Drug resistance limits treatment success in a subset of lung cancers driven by ROS1 gene alterations. Using patient‐derived cells and computer simulations, we studied three key mutations and how they affect five targeted drugs. The mutations reduced drug effectiveness in different ways by altering protein structure and behavior.
Farhan Ul Haq, Marc Terrones, Felicia Rodrigues Fortes, Anne Schepers, Alessia Denis, Christophe Deben, Ken Op de Beeck, Guy Van Camp, Geert Vandeweyer   +8 more
wiley   +1 more source

ZW4864‐mediated inhibition of the β‐catenin/BCL9/BCL9L complex reveals therapeutic potential in bladder cancer

Molecular Oncology, EarlyView.
BCL9 and BCL9L drive bladder cancer progression by enhancing β‐catenin signaling, promoting proliferation, migration, invasion, and organoid growth. Genetic depletion of BCL9(L) suppresses malignant phenotypes, while pharmacological disruption of the β‐catenin/BCL9(L) complex with ZW4864 inhibits canonical Wnt signaling and tumor‐associated cellular ...
Roland Kotolloshi, Mandy Berndt‐Paetz, Eileen Lerner, Gregoire Najjar, Anca Azoitei, Krishna Pal Singh, Shailendra Kumar Gupta, Olaf Wolkenhauer, Cagatay Günes, Otmar Huber, Marc‐Oliver Grimm, Daniel Steinbach   +11 more
wiley   +1 more source

Figure S3 from A Blood-based Assay for Assessment of Tumor Mutational Burden in First-line Metastatic NSCLC Treatment: Results from the MYSTIC Study

, 2023
Han Si, Michael Kuziora, Katie Quinn, Elena Helman, Jiabu Ye, Feng Liu, Urban Scheuring, Solange Peters, Naiyer A. Rizvi, Philip Z. Brohawn, Koustubh Ranade, Brandon W. Higgs, Kimberly C. Banks, Vikram K. Chand, Rajiv Raja   +14 more
openalex   +1 more source

A Systematic Review and Meta-Analysis of the Impact of Tumour Mutation Burden on Survival Outcomes in Solid Tumours. [PDF]

Cancer Med
Meng A, Yuile A, Sim HW, Thavaneswaran S, Noor H, Yeung J, Mehta A, Powell J, Zaman A.   +8 more
europepmc   +1 more source

Translating whole‐genome doubling into precision medicine in cancer

Molecular Oncology, EarlyView.
Whole‐genome doubling creates a WGD‐positive tumor state characterized by persistent chromosomal instability, karyotypic diversification, and cellular stress. These same biological pressures drive aggressive tumor evolution while exposing therapeutic vulnerabilities, providing a rationale for WGD‐informed precision medicine. Whole‐genome doubling (WGD)
Sejung Lee, Junghyeok Lim, Jinhyuk Bhin
wiley   +1 more source

To be or low TMB (tumor mutational burden)

Translational Cancer Research
Falk, Markus, Tiemann, Markus, Ficker, Joachim H., Brueckl, Wolfgang M.   +3 more
openaire   +2 more sources

High Tumor Mutation Burden [PDF]

, 2020
openaire   +1 more source

Figure S4 from PD-L1 Negative Status is Associated with Lower Mutation Burden, Differential Expression of Immune-Related Genes, and Worse Survival in Stage III Melanoma

, 2023
Jason Madore, Dario Strbenac, Ricardo E. Vilain, Alexander M. Menzies, Jeen Y. H. Yang, John F. Thompson, Georgina V. Long, Graham J. Mann, Richard A. Scolyer, James S. Wilmott   +9 more
openalex   +1 more source

Impact of chemotherapy exposure on tumor mutation burden in advanced colorectal cancer. [PDF]

Sci Rep
Sudo T, Nagasu S, Tanaka T, Fujiyoshi K, Kawamoto Y, Shimamura S, Fukuda J, Kikuchi M, Shigyo H, Koushi K, Shigaki T, Yoshida N, Yoshida T, Miwa K, Koga H, Fujita F.   +15 more
europepmc   +1 more source